Stem definition | Drug id | CAS RN |
---|---|---|
HIV protease inhibitors | 1240 | 226700-79-4 |
Dose | Unit | Route |
---|---|---|
1.40 | g | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 0.31 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 0 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 67.81 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
Date | Agency | Company | Orphan |
---|---|---|---|
Oct. 20, 2003 | FDA | VIIV HLTHCARE |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Viral mutation identified | 110.37 | 80.03 | 17 | 286 | 1612 | 50603209 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Lipodystrophy acquired | 73.01 | 34.97 | 18 | 1094 | 3076 | 29570339 |
Virologic failure | 59.35 | 34.97 | 15 | 1097 | 2832 | 29570583 |
Heart transplant rejection | 50.02 | 34.97 | 11 | 1101 | 1140 | 29572275 |
Viral mutation identified | 46.41 | 34.97 | 12 | 1100 | 2476 | 29570939 |
Hypertriglyceridaemia | 45.04 | 34.97 | 15 | 1097 | 7460 | 29565955 |
Immune reconstitution inflammatory syndrome | 40.49 | 34.97 | 14 | 1098 | 7788 | 29565627 |
Blood HIV RNA increased | 40.16 | 34.97 | 9 | 1103 | 1015 | 29572400 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Viral mutation identified | 108.62 | 40.53 | 22 | 1111 | 3324 | 64494275 |
Lipodystrophy acquired | 104.56 | 40.53 | 22 | 1111 | 4005 | 64493594 |
Virologic failure | 78.93 | 40.53 | 17 | 1116 | 3449 | 64494150 |
Drug resistance | 64.74 | 40.53 | 24 | 1109 | 35078 | 64462521 |
CSF HIV escape syndrome | 64.73 | 40.53 | 10 | 1123 | 315 | 64497284 |
Abortion spontaneous | 56.87 | 40.53 | 20 | 1113 | 25123 | 64472476 |
Hypertriglyceridaemia | 50.30 | 40.53 | 15 | 1118 | 11190 | 64486409 |
Blood HIV RNA increased | 49.57 | 40.53 | 10 | 1123 | 1474 | 64496125 |
Immune reconstitution inflammatory syndrome | 44.51 | 40.53 | 14 | 1119 | 12456 | 64485143 |
None
Source | Code | Description |
---|---|---|
ATC | J05AE07 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIVIRALS FOR SYSTEMIC USE DIRECT ACTING ANTIVIRALS Protease inhibitors |
FDA MoA | N0000000246 | HIV Protease Inhibitors |
MeSH PA | D000900 | Anti-Bacterial Agents |
MeSH PA | D019380 | Anti-HIV Agents |
MeSH PA | D000890 | Anti-Infective Agents |
MeSH PA | D044966 | Anti-Retroviral Agents |
MeSH PA | D000904 | Antibiotics, Antitubercular |
MeSH PA | D000995 | Antitubercular Agents |
MeSH PA | D000998 | Antiviral Agents |
MeSH PA | D004791 | Enzyme Inhibitors |
MeSH PA | D017320 | HIV Protease Inhibitors |
MeSH PA | D011480 | Protease Inhibitors |
MeSH PA | D000084762 | Viral Protease Inhibitors |
FDA EPC | N0000175889 | Protease Inhibitor |
FDA MoA | N0000182141 | Cytochrome P450 3A4 Inhibitors |
FDA MoA | N0000185506 | Cytochrome P450 3A4 Inducers |
FDA MoA | N0000191264 | P-Glycoprotein Inducers |
CHEBI has role | CHEBI:35660 | HIV protease inhibitors |
CHEBI has role | CHEBI:36044 | antiviral drugs |
CHEBI has role | CHEBI:50266 | Prodrugs |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Human immunodeficiency virus infection | indication | 86406008 | DOID:526 |
Prevention of HIV Infection after Exposure | off-label use | ||
Hypercholesterolemia | contraindication | 13644009 | |
Myocardial infarction | contraindication | 22298006 | DOID:5844 |
Hereditary factor VIII deficiency disease | contraindication | 28293008 | DOID:12134 |
Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
Hereditary factor IX deficiency disease | contraindication | 41788008 | DOID:12259 |
Hemolytic anemia | contraindication | 61261009 | DOID:583 |
Chronic type B viral hepatitis | contraindication | 61977001 | |
Lipodystrophy | contraindication | 71325002 | DOID:811 |
Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
Hyperglycemia | contraindication | 80394007 | DOID:4195 |
Kidney stone | contraindication | 95570007 | |
Chronic hepatitis C | contraindication | 128302006 | |
Liver function tests abnormal | contraindication | 166603001 | |
Disease of liver | contraindication | 235856003 | DOID:409 |
Hypertriglyceridemia | contraindication | 302870006 | |
Cardiovascular event risk | contraindication | 395112001 | |
Breastfeeding (mother) | contraindication | 413712001 | |
Disorder of coronary artery | contraindication | 414024009 | |
Obesity | contraindication | 414916001 | DOID:9970 |
Ketoacidosis in diabetes mellitus | contraindication | 420422005 | DOID:1837 |
Smokes tobacco daily | contraindication | 449868002 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 1.13 | acidic |
pKa2 | 6.35 | acidic |
pKa3 | 1.8 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Pol polyprotein | Enzyme | INHIBITOR | CHEMBL | CHEMBL | |||||
Gag-Pol polyprotein | Polyprotein | WOMBAT-PK |
ID | Source |
---|---|
4021412 | VUID |
N0000148827 | NUI |
D02497 | KEGG_DRUG |
226700-81-8 | SECONDARY_CAS_RN |
4021158 | VANDF |
4021412 | VANDF |
C1176315 | UMLSCUI |
CHEBI:82941 | CHEBI |
CHEBI:40050 | CHEBI |
478 | PDB_CHEM_ID |
CHEMBL1664 | ChEMBL_ID |
CHEMBL1200734 | ChEMBL_ID |
DB01319 | DRUGBANK_ID |
C426859 | MESH_SUPPLEMENTAL_RECORD_UI |
C095108 | MESH_SUPPLEMENTAL_RECORD_UI |
8011 | INN_ID |
WOU1621EEG | UNII |
131536 | PUBCHEM_CID |
DB00701 | DRUGBANK_ID |
228656 | RXNORM |
17646 | MMSL |
262160 | MMSL |
64492 | MMSL |
8067 | MMSL |
d04428 | MMSL |
d04901 | MMSL |
004510 | NDDF |
004511 | NDDF |
007752 | NDDF |
116088006 | SNOMEDCT_US |
387006009 | SNOMEDCT_US |
407017006 | SNOMEDCT_US |
407018001 | SNOMEDCT_US |
412393004 | SNOMEDCT_US |
65016 | PUBCHEM_CID |
C0754188 | UMLSCUI |
7751 | INN_ID |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Fosamprenavir Calcium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-3520 | TABLET, FILM COATED | 700 mg | ORAL | ANDA | 27 sections |
LEXIVA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 49702-207 | TABLET, FILM COATED | 700 mg | ORAL | NDA | 26 sections |
LEXIVA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 49702-207 | TABLET, FILM COATED | 700 mg | ORAL | NDA | 26 sections |
LEXIVA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 49702-208 | SUSPENSION | 50 mg | ORAL | NDA | 26 sections |
LEXIVA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 49702-208 | SUSPENSION | 50 mg | ORAL | NDA | 26 sections |
LEXIVA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 53808-0281 | TABLET, FILM COATED | 700 mg | ORAL | NDA | 26 sections |
LEXIVA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 53808-1010 | TABLET, FILM COATED | 700 mg | ORAL | NDA | 25 sections |
Fosamprenavir Calcium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63304-583 | TABLET, COATED | 700 mg | ORAL | ANDA | 25 sections |